What are the leading stocks of stock medicine?

Domestic generic drug leading stocks: Hengrui Pharma, Huadong Pharmaceutical, Huahai Pharmaceutical, Puli Pharmaceutical, Jingxin Pharmaceutical and Xinlitai.

1, Hengrui Pharma

Jiangsu hengrui Pharmaceutical Co., Ltd. was established on April, 2007 1997 with the approval of Jiangsu Provincial People's Government and initiated by five sponsors including Lianyungang Hengrui Group Co., Ltd. It is the largest research, development and production base of anti-tumor drugs in China.

2. East China Medicine

Hangzhou Huadong Pharmaceutical Group Company, formerly known as Zhejiang Pharmaceutical Factory, was founded in 1952, and later renamed Hangzhou No.2 Pharmaceutical Factory and Hangzhou Huadong Pharmaceutical Factory.

199265438+February 16, Hangzhou Huadong Pharmaceutical Group Company was established on the basis of Hangzhou Huadong Pharmaceutical Factory, and has now developed into a joint-stock enterprise-Huadong Pharmaceutical Co., Ltd., four Sino-foreign joint ventures (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Hangzhou Moshadong Pharmaceutical Co., Ltd., Hangzhou Jiuyuan Genetic Engineering Co., Ltd., Zhejiang Huayi Pharmaceutical Co., Ltd.).

3. Huahai Pharmaceutical

Zhejiang Huahai Pharmaceutical Co., Ltd. was founded in 1989, formerly known as Linhai Hongqiao Synthetic Chemical Plant. 200 1 changed to Zhejiang huahai pharmaceutical co., ltd as a whole. In March 2003, the company's shares were successfully listed on the Shanghai Stock Exchange. Stock abbreviation: Huahai Pharmaceutical, stock code: 60052 1.

4. Puli Pharmaceutical

Established in 1992, Hainan Puli Pharmaceutical Co., Ltd. is a high-tech enterprise specializing in the research, development, production and sales of chemical pharmaceutical preparations, and has passed the certification of leading pharmaceutical enterprises in China. The company has two wholly-owned subsidiaries, Zhejiang Puli Pharmaceutical Co., Ltd. and Hangzhou Saili Pharmaceutical Research Institute.

5. Jingxin Pharmaceutical

Zhejiang Jingxin Pharmaceutical Co., Ltd. was founded in 1974, and has now developed into a national key high-tech enterprise and one of the top 100 pharmaceutical enterprises in China. In July 2004, it was successfully listed on Shenzhen Stock Exchange.

6. Xinlitai

Shenzhen Xinlitai Pharmaceutical Co., Ltd. was approved by the Ministry of Commerce of People's Republic of China (PRC) "Reply on Agreeing to the Restructuring of Shenzhen Xinlitai Pharmaceutical Co., Ltd. into a Chinese-foreign Joint-stock Enterprise" (CSRC Permit [2007] 10 16) and obtained the "Approval Certificate of China People's Taiwan, Hong Kong, Macao and Overseas Chinese Investment Enterprise" issued by the Ministry of Commerce. On June 29th, 2007, Shenzhen Xinlitai Pharmaceutical Co., Ltd. (hereinafter referred to as "Shenzhen Xinlitai") was established as a wholly foreign-owned company with a registered capital of 85 million yuan, and obtained the Business License of Enterprise as a Legal Person with the registration number of 44030150124347.

Extended data policies and regulations

2065438+April 3, 2008, the General Office of the State Council issued the Opinions on Reforming and Perfecting the Policy of Supply Guarantee and Use of Generic Drugs (hereinafter referred to as the Opinions), pointing out that it is necessary to focus on the outstanding problems faced by the generic drug industry, promote the structural reform of the supply side of the pharmaceutical industry, improve the ability of drug supply guarantee, reduce the drug cost burden of the whole society, ensure the drug demand of the broad masses of the people, and accelerate China's leap from a pharmaceutical power to a pharmaceutical power, so as to promote the research and development of generic drugs and generic drugs.

References:

People's Daily Online "Policies to Promote the Substitution of Generic Drugs and Accelerate Imports, Optimistic about 8 Leading Stocks"